title: Urinary angiotensin converting enzyme 2 increases in patients with type 2 diabetic mellitus.
abstract: OBJECTIVE
  Angiotensin converting enzyme 2 (ACE2) is highly expressed in the kidney and recognized to be renoprotective by degrading Angiotensin II to Angiotensin (1-7) in diabetic nephropathy. However, little is known about the role of urinary ACE2 (UACE2) in diabetes. The present study was performed to evaluate UACE2 levels in type 2 diabetic patients with various degrees of albuminuria and its associations with metabolic parameters. The effect of RAS inhibitors on UACE2 excretion was also assessed.
  
  
  METHODS
  A total of 132 type 2 diabetic patients with different degrees of albuminuria and 34 healthy volunteers were studied. UACE2 levels and activity were measured.
  
  
  RESULTS
  Compared to healthy controls, UACE2 to creatinine (UACE2/Cr) levels were significantly increased in both albuminuric and non-albuminuric diabetic patients. UACE2/Cr levels were much higher in hypertensive diabetic patients compared with their normotensive counterparts and treatment with RAS inhibitors markedly attenuated the augmentation. Furthermore, UACE2/Cr was positively correlated with fasting blood glucose, hemoglobin A1C (HbA1C), triglyceride, and total cholesterol. In multiple regression analysis, UACE2/Cr was independently predicted by HbA1C and RAS inhibitors treatment.
  
  
  CONCLUSIONS
  UACE2 increased in type 2 diabetic patients with various degrees of albuminuria and RAS inhibitors suppresses UACE2 excretion. UACE2 might potentially function as a marker for monitoring the metabolic status and therapeutic response of RAS inhibitors in diabetes.
authors: Department of Nephrology, Peking University Third Hospital, Beijing 100191, China.
authors: Yaoxian
authors: Y
authors: Liang
authors: Hui
authors: H
authors: Deng
authors: Shuhong
authors: S
authors: Bi
authors: Zhuan
authors: Z
authors: Cui
authors: Lata
authors: L
authors: A
authors: Danxia
authors: D
authors: Zheng
authors: Yue
authors: Y
authors: Wang
mesh_terms: D000368:Aged; D000419:Albuminuria / Q000235:genetics; D000085962:Angiotensin-Converting Enzyme 2; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000652:urine; D003404:Creatinine / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000652:urine*; D003928:Diabetic Nephropathies / Q000652:urine; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications; D006977:Hypertension, Renal / Q000652:urine; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000652:urine*; D012016:Reference Values; D012084:Renin-Angiotensin System / Q000187:drug effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D015415:Biomarkers; D003404:Creatinine; D007703:Peptidyl-Dipeptidase A; C000705307:ACE2 protein, human; D000085962:Angiotensin-Converting Enzyme 2